Free Trial
→ Trump's gold order: the announcement they won't put on the front page (From Reagan Gold Group) (Ad)tc pixel
NASDAQ:SXTP

60 Degrees Pharmaceuticals Q3 2025 Earnings Report

60 Degrees Pharmaceuticals logo
$1.42 -0.11 (-7.19%)
Closing price 06/5/2026 04:00 PM Eastern
Extended Trading
$1.44 +0.02 (+1.41%)
As of 06/5/2026 06:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

60 Degrees Pharmaceuticals EPS Results

Actual EPS
-$2.64
Consensus EPS
-$4.84
Beat/Miss
Beat by +$2.20
One Year Ago EPS
N/A

60 Degrees Pharmaceuticals Revenue Results

Actual Revenue
($0.01) million
Expected Revenue
$0.38 million
Beat/Miss
Missed by -$389.13 thousand
YoY Revenue Growth
N/A

60 Degrees Pharmaceuticals Announcement Details

Quarter
Q3 2025
Date
11/13/2025
Time
Before Market Opens
Conference Call Date
Thursday, November 13, 2025
Conference Call Time
4:00PM ET

Upcoming Earnings

60 Degrees Pharmaceuticals' Q2 2026 earnings is estimated for Wednesday, August 12, 2026, based on past reporting schedules, with a conference call scheduled on Friday, August 14, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

60 Degrees Pharmaceuticals' Q3 2025 Earnings ReleaseEarnings Release
(8-K)
60 Degrees Pharmaceuticals' Q3 2025 Quarterly ReportQuarterly Report
(10-Q)

60 Degrees Pharmaceuticals Earnings Headlines

60 Degrees Pharmaceuticals Announces Early Enrollment of First Seasonal Patient in Clinical Trial of Tafenoquine for Patients Hospitalized with Babesiosis
May 26, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/26/3301055/0/en/60-degrees-pharmaceuticals-announces-early-enrollment-of-first-seasonal-patient-in-clinical-trial-of-tafenoquine-for-patients-hospitalized-with-babesiosis.html
HC Wainwright & Co. downgrades 60 Degrees Pharmaceuticals (SXTP)
May 21, 2026  |  msn.comhttps://www.msn.com/en-us/health/other/hc-wainwright-co-downgrades-60-degrees-pharmaceuticals-sxtp/ar-AA23H6gv
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free.tc pixel
June 7 at 1:00 AM  |  Reagan Gold Group (Ad)
60 Degrees Pharmaceuticals Announces First Quarter 2026 Results
May 15, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/15/3295850/0/en/60-degrees-pharmaceuticals-announces-first-quarter-2026-results.html
60 Degrees Pharmaceuticals (SXTP) price target decreased by 19.89% to 14.38
April 30, 2026  |  msn.comhttps://www.msn.com/en-us/money/topstocks/60-degrees-pharmaceuticals-sxtp-price-target-decreased-by-19-89-to-14-38/ar-AA21YV1N
60 Degrees Pharma Announces ARAKODA (tafenoquine) for Malaria Prevention is Now Available on Runway Health Travel Website
April 15, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/60-degrees-pharma-announces-arakoda-tafenoquine-for-malaria-prevention-is-now-available-on-runway-health-travel-website-1036024547
See More 60 Degrees Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like 60 Degrees Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on 60 Degrees Pharmaceuticals and other key companies, straight to your email.

About 60 Degrees Pharmaceuticals

60 Degrees Pharmaceuticals (NASDAQ:SXTP), Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is headquartered in Washington, the District of Columbia.

View 60 Degrees Pharmaceuticals Profile
Earnings Tools